These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36576574)

  • 21. Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
    Brown JWL; Chowdhury A; Kanber B; Prados Carrasco F; Eshaghi A; Sudre CH; Pardini M; Samson RS; van de Pavert SH; Wheeler-Kingshott CG; Chard DT
    Mult Scler; 2020 May; 26(6):679-687. PubMed ID: 30957691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
    Kaunzner UW; Kang Y; Zhang S; Morris E; Yao Y; Pandya S; Hurtado Rua SM; Park C; Gillen KM; Nguyen TD; Wang Y; Pitt D; Gauthier SA
    Brain; 2019 Jan; 142(1):133-145. PubMed ID: 30561514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
    Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
    J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis.
    Bieniek M; Altmann DR; Davies GR; Ingle GT; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1036-9. PubMed ID: 16793860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Periventricular gradient of T
    Vaneckova M; Piredda GF; Andelova M; Krasensky J; Uher T; Srpova B; Havrdova EK; Vodehnalova K; Horakova D; Hilbert T; Maréchal B; Fartaria MJ; Ravano V; Kober T
    Neuroimage Clin; 2022; 34():103009. PubMed ID: 35561554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid PET in pseudotumoral multiple sclerosis.
    Matías-Guiu JA; Cabrera-Martín MN; Cortés-Martínez A; Pytel V; Moreno-Ramos T; Oreja-Guevara C; Carreras JL; Matías-Guiu J
    Mult Scler Relat Disord; 2017 Jul; 15():15-17. PubMed ID: 28641766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal change in TSPO PET imaging in progressive multiple sclerosis.
    Kang Y; Pandya S; Zinger N; Michaelson N; Gauthier SA
    Ann Clin Transl Neurol; 2021 Aug; 8(8):1755-1759. PubMed ID: 34310086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.
    Khaleeli Z; Sastre-Garriga J; Ciccarelli O; Miller DH; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1076-82. PubMed ID: 17287235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.
    Bezukladova S; Tuisku J; Matilainen M; Vuorimaa A; Nylund M; Smith S; Sucksdorff M; Mohammadian M; Saunavaara V; Laaksonen S; Rokka J; Rinne JO; Rissanen E; Airas L
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.
    Laule C; Vavasour IM; Zhao Y; Traboulsee AL; Oger J; Vavasour JD; Mackay AL; Li DK
    Mult Scler; 2010 Jun; 16(6):670-7. PubMed ID: 20558500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions.
    Fransen NL; Hsiao CC; van der Poel M; Engelenburg HJ; Verdaasdonk K; Vincenten MCJ; Remmerswaal EBM; Kuhlmann T; Mason MRJ; Hamann J; Smolders J; Huitinga I
    Brain; 2020 Jun; 143(6):1714-1730. PubMed ID: 32400866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
    Kaunzner UW; Kang Y; Monohan E; Kothari PJ; Nealon N; Perumal J; Vartanian T; Kuceyeski A; Vallabhajosula S; Mozley PD; Riley CS; Newman SM; Gauthier SA
    Mult Scler Relat Disord; 2017 Jul; 15():27-33. PubMed ID: 28641769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.
    Tur C; Ramagopalan S; Altmann DR; Bodini B; Cercignani M; Khaleeli Z; Miller DH; Thompson AJ; Ciccarelli O
    Neurology; 2014 Nov; 83(19):1712-8. PubMed ID: 25298310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis.
    Leech S; Kirk J; Plumb J; McQuaid S
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):86-98. PubMed ID: 17239011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
    Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS.
    Pardini M; Petracca M; Harel A; Fleysher L; Oesingmann N; Bommarito G; Fabian M; Chard D; Lublin F; Inglese M
    Neuroimage Clin; 2017; 16():111-115. PubMed ID: 28794971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discriminative clinical and neuroimaging features of motor-predominant hereditary diffuse leukoencephalopathy with axonal spheroids and primary progressive multiple sclerosis: A preliminary cross-sectional study.
    Saitoh BY; Yamasaki R; Hiwatashi A; Matsushita T; Hayashi S; Mitsunaga Y; Maeda Y; Isobe N; Yoshida K; Ikeda SI; Kira JI
    Mult Scler Relat Disord; 2019 Jun; 31():22-31. PubMed ID: 30901701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study.
    Margoni M; Pagani E; Meani A; Storelli L; Mesaros S; Drulovic J; Barkhof F; Vrenken H; Strijbis E; Gallo A; Bisecco A; Pareto D; Sastre-Garriga J; Ciccarelli O; Yiannakas M; Palace J; Preziosa P; Rocca MA; Filippi M;
    J Neurol Neurosurg Psychiatry; 2022 Jul; 93(7):741-752. PubMed ID: 35580993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.